Markus Hansson
0000-0002-7715-4548
Publication & Citation Trends
Publications
0 total
548PAttitudes towards the use of AI on electronic health records for phenotyping and screening of rare diseases: a systematic review
Cited by 0
Semantic Scholar
Analysis of Patients With Prior BCMA-Targeted Therapy and Those Achieving CR in REALiTAL: A Multi-Country Observational Study of Talquetamab in RRMM Outside of Clinical Trials
Cited by 0
Semantic Scholar
P-030 Low Infection Rates in Patients (pts) With Relapsed/Refractory Myeloma (RRMM) Treated With Alnuctamab (ALNUC) in a Setting of Infection Reduction Strategies (IRS) and Less Frequent Dosing
Cited by 0
Semantic Scholar
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study OA
Cited by 27
Semantic Scholar
P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
Cited by 0
Semantic Scholar
Success Factors in the Process of Establishing a Techcenter
Cited by 0
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(113)
Protein Degradation and Inhibitors
(47)
Cancer Treatment and Pharmacology
(27)
Peptidase Inhibition and Analysis
(26)
Immune Cell Function and Interaction
(24)
Affiliations
Scania (Sweden)
Scripps Health
Lund University
Aalborg University Hospital
Sahlgrenska University Hospital